Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.96 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.85 |
| ▸ | HPGD | P15428 | 1/20 | 0.85 |
| ▸ | RARB | P10826 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | RARA | P10276 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | ESR1 | P03372 | 2/20 | 0.60 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.60 |
| ▸ | TACR2 | P21452 | 2/20 | 0.60 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | SHBG | P04278 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9522105 | 1.00 | ALDH1A1 (0.96) | ALDH1A1HSD17B10HPGDRARBMEN1 | |
| SCHEMBL8337401 | 1.00 | ALDH1A1 (0.96) | ALDH1A1HSD17B10HPGDRARBMEN1 | |
| SCHEMBL15261049 | 1.00 | ALDH1A1 (0.96) | ALDH1A1HSD17B10HPGDRARBMEN1 | |
| SCHEMBL2674656 | 1.00 | ALDH1A1 (0.96) | ALDH1A1HSD17B10HPGDRARBMEN1 | |
| SCHEMBL9523042 | 1.00 | ALDH1A1 (0.96) | ALDH1A1HSD17B10HPGDRARBMEN1 | |
| SCHEMBL846163 | 0.98 | ALDH1A1 (1.00) | ALDH1A1HSD17B10HPGDRARBMEN1 | |
| SCHEMBL10895715 | 0.93 | ALDH1A1 (0.89) | ALDH1A1HSD17B10HPGDRARBMEN1 | |
| SCHEMBL1445637 | 0.92 | ALDH1A1 (1.00) | ALDH1A1HSD17B10HPGDRARBMEN1 | |
| SCHEMBL12967551 | 0.92 | ALDH1A1 (0.81) | ALDH1A1HSD17B10HPGDRARBMEN1 | |
| Hydrochloric Acid SCHEMBL2529595 | 0.90 | ALDH1A1 (0.96) | ALDH1A1HSD17B10HPGDRARBTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063959-A1 | Esters and amides as PLA2 inhibitors | FUKAMI NAOKI (JP) | 2004-04-01 | — | — | US | disclosed |
| US-20020169326-A1 | Esters and amides as PLA2 inhibitors | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 2002-11-14 | — | — | US | disclosed |
| EP-0854863-B1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-10-30 | — | — | EP | disclosed |
| US-20020019416-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-14 | — | — | US | disclosed |
| CN-1056602-C | Esters and amides as PLA2 inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-09-20 | — | — | CN | disclosed |
| CN-1197450-A | Esters and amides as phospholipase A2 inhibitors | FUJISAWA PHARMACEUTICAL CO (JP) | 1998-10-28 | — | — | CN | disclosed |
| EP-0854863-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-07-29 | — | — | EP | disclosed |
| WO-1997003951-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-02-06 | — | — | WO | disclosed |
| US-5128472-A | Electrooptical display materials, ferroelectric display | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1992-07-07 | — | — | US | disclosed |
| US-4997942-A | 2,4-disubstituted pyrazine derivatives, pyrimidine derivatives, and liquid crystal containing the same | DAINIPPON INK AND CHEMICAL, INC. (JP) | 1991-03-05 | — | — | US | disclosed |
| EP-0339252-A2 | 2,5-disubstituted pyrazine derivatives, pyrimidine derivatives, and liquid crystal containing the same | DAINIPPON INK AND CHEMICALS, INC. (JP) | 1989-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063959-A1 | Esters and amides as PLA2 inhibitors | PLA2G4A, PLA2G2D, PLA2G4B | ALDH1A1 800/4885HSD17B10 201/4885HPGD 592/4885 |
| US-20020019416-A1 | ESTERS AND AMIDES AS PLA2 INHIBITORS | PLA2G4A, PLA2G4B, PLA2G1B | ALDH1A1 700/4885HSD17B10 195/4885HPGD 677/4885 |
| US-20020169326-A1 | Esters and amides as PLA2 inhibitors | PLA2G4A, PLA2G2D, PLA2G4B | ALDH1A1 737/4885HSD17B10 191/4885HPGD 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.